Improved Modeling of Plutonium-DTPA Decorporation

Dumit, Sara; Avtandilashvili, Maia; Strom, Daniel J.; McComish, Stacey L.; Tabatadze, George; Tolmachev, Sergei Y.

doi:10.1667/rr15188.1

Cited by 23 publications

(19 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With regard to the liver, a chelation of hepatic transuranic deposits in animals ( Bhattacharyya et al 1978 ; Grémy et al 2016 ) and humans ( Roedler et al 1989 ; James et al 2007 ) has been reported by several authors. More recently, Dumit et al (2019c and 2020b ) considered also that plutonium chelation can take place in systemic soft tissues including the liver and parts of skeleton.…”

Section: Resultsmentioning

confidence: 99%

Interpretation of Enhanced Fecal and Urinary Plutonium Excretion Data under a 2-y Regular DTPA Treatment Started Months after Intake

2021

View full text Add to dashboard Cite

In a worker who had internalized plutonium, most likely through inhalation of a somewhat soluble compound, an extensive diethylenetriaminepentaacetate (DTPA) treatment regimen was initiated several months after contamination. Numerous radiotoxicological analyses were performed in both fecal and urinary specimens collected, sometimes for three consecutive days after DTPA administration. Activity measurements showed the continued effectiveness of DTPA intravenous infusions in removing plutonium from tissues of retention even if the treatment regimen started very belatedly after contamination. In the present case, the activity excreted through urine within the first 24-h after a DTPA infusion contributed only about half of that activity excreted within the first three days (i.e., the cumulative activity of the first three 24-h urine collections). In addition, the careful study of the data revealed that DTPA-induced excretion of plutonium via fecal pathway significantly contributed to the overall decorporation. The intracellular chelation of plutonium may be responsible for this enhanced excretion of activity in feces as well as for the delayed and sustained increased clearance of activity in urine. The authors would suggest that the occupational physicians offer to individuals who internalized moderately soluble or soluble plutonium compounds undergo a long-term DTPA treatment, especially when it is not initiated promptly after intake. Under this scenario, measurements of plutonium in successive urine and fecal collections after treatment should be required to get a better estimate of the therapeutic benefit. Also, intracellular chelation and fecal route should be taken into account for better interpretation of radiotoxicological data and modeling of plutonium kinetics under delayed DTPA treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

Interpretation of Enhanced Fecal and Urinary Plutonium Excretion Data under a 2-y Regular DTPA Treatment Started Months after Intake

2021

View full text Add to dashboard Cite

show abstract

“…Over the course of time, Pu nuclides become more tightly bound to tissues, thus making it much less available for chelation. Nonetheless, several authors have considered the ability of multiple DTPA systemic treatments to mobilize some Pu/Am retained in both hepatic and skeletal tissues in man (Roedler et al 1989; James et al 2007; Dumit et al 2019c; Dumit et al 2020; Grémy et al 2021). Circulating Pu, resulting from either blood absorption from lungs or release from extra-pulmonary tissues (re-circulation), could also be chelated by DTPA molecules.…”

Section: Data Interpretationmentioning

confidence: 99%

Excretion of Pu-238 during Long-term Chelation Therapy by Repeated DTPA Inhalation

2022

View full text Add to dashboard Cite

An individual underwent an extensive diethylenetriaminepentaacetate (DTPA) chelation therapy that started several months after plutonium incorporation, most likely by inhalation of a soluble compound. After receiving multiple intravenous infusions of DTPA, the patient continued the treatment by pulmonary delivery of aerosolized DTPA. The purpose of the present work is to provide and discuss the bioassay data obtained during the DTPA aerosol therapy and compare them with those under the DTPA infusion therapy that have been largely interpreted elsewhere. As with DTPA given intravenously, each delayed DTPA inhalation increased the clearance of plutonium not only in urine but also in feces, thus demonstrating the ability to remove plutonium retained by extrapulmonary tissues. Also, the slow decline of increased plutonium urinary elimination together with enhanced fecal excretion are two features coherent with the contribution of intracellular chelation to overall decorporation. The therapeutic benefit of DTPA inhalation appeared lower than with DTPA infusion, most likely due to a lower amount of DTPA reaching the systemic compartments where plutonium chelation predominates. The results suggest that DTPA administration through aerosol could be an alternative to the invasive procedure using a needle, i.e., intravenous injection/infusion, when protracted decorporation therapy is needed following transuranic internalization. Indeed, the patient may be more inclined to undergo a chelation treatment for a longer period because taking DTPA by inhalation may make it less cumbersome and painful.

show abstract

“…The DTPA calcium sodium salt is a commonly used metal complexing agent with excellent biosafety and is recognized as a decontaminator of various radionuclides. [13,14] Sodium alginate is a floc reinforcer with a large number of carboxyl groups on the molecular chain that can effectively adsorb metal ions. As a natural polymer material, sodium alginate has good biosafety and biocompatibility, is inexpensive, and it promotes hemostasis and healing.…”

Section: Discussionmentioning

confidence: 99%

Development and Characterization of a Novel Hydrogel for the Decontaminating of Radionuclide‐Contaminated Skin Wounds

Cui

Zhao

et al. 2021

Macromolecular Bioscience

View full text Add to dashboard Cite

show abstract

Improved Modeling of Plutonium-DTPA Decorporation

Cited by 23 publications

References 46 publications

Interpretation of Enhanced Fecal and Urinary Plutonium Excretion Data under a 2-y Regular DTPA Treatment Started Months after Intake

Interpretation of Enhanced Fecal and Urinary Plutonium Excretion Data under a 2-y Regular DTPA Treatment Started Months after Intake

Excretion of Pu-238 during Long-term Chelation Therapy by Repeated DTPA Inhalation

Development and Characterization of a Novel Hydrogel for the Decontaminating of Radionuclide‐Contaminated Skin Wounds

Contact Info

Product

Resources

About